Eli Lilly and Company (FRA:LLY)
704.20
+2.70 (0.38%)
At close: Oct 23, 2025
Eli Lilly and Company Revenue
Eli Lilly and Company had revenue of $15.56B USD in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly and Company had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
13.85
Revenue / Employee
$1.13M
Employees
47,000
Market Cap
628.11B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 139.36B |
| Deutsche Telekom AG | 120.55B |
| Allianz SE | 109.02B |
| Siemens Aktiengesellschaft | 78.30B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
| Siemens Energy AG | 38.39B |
| SAP SE | 35.89B |
| Deutsche Bank Aktiengesellschaft | 30.07B |
Eli Lilly and Company News
- 11 hours ago - Lilly and Cipla tie up to broaden access of weight-loss therapy - The Times of India
- 13 hours ago - 10 stocks primed for growth in the S&P 500's cheapest sectors - Market Watch
- 14 hours ago - Eli Lilly (LLY) Partners with Cipla to Market Tirzepatide in India - GuruFocus
- 17 hours ago - Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats - Seeking Alpha
- 18 hours ago - Eli Lilly allows Cipla to sell weight loss drug under new brand in India - Reuters
- 1 day ago - Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data? - Benzinga
- 1 day ago - 3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report - The Motley Fool
- 2 days ago - Notable Tuesday Option Activity: LUV, TMO, LLY - Nasdaq